Price movement over the last 24 hours
ADMA Biologics Inc vs Block Inc — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Block Inc trades at $76.14 (market cap $46.16B). The key difference: Block Inc is far larger — about 21.7× ADMA Biologics Inc's market cap, and Block Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | XYZ | |
|---|---|---|
Market Cap | $2.13B | $46.16B |
Sector | Health | Technology |
52-Week High | $20.38 | $81.11 |
52-Week Low | $7.60 | $49.04 |
Enterprise Value | $2.20B | $41.03B |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
XYZ (Block, Inc.) trades at $77.56, down 1.61% today, with a bullish technical signal from moving averages and strong analyst consensus (74% buy ratings). Recent earnings show mixed results with Q1 2026 beating expectations, while cash flow turned negative in 2025 due to heavy investing. The company continues expanding its Square platform through AI integrations and enterprise partnerships, positioning for growth in digital payments.
Outlook remains positive with a $87.71 consensus price target, though high P/E of 61.66 and declining net income margins pose valuation concerns. Key risks include execution on AI initiatives and competitive pressure in fintech. Institutional sentiment is supportive, but investors should monitor Q2 2026 earnings due August 5, 2026 for confirmation of growth trajectory.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →